Significance of reporting ABO serology post ABOi HSCT engraftment

To test the clinical significance of re-emergence, post 30 days HSCT engraftment, of ABO
isoagglutinins against:
- the patient ABO in minor ABOi Tx
- the HSCT ABO donor in major ABOi Tx
To make a recommendation on reporting any change in ABO serologic evaluation in the
forward and reverse ABO typing post HSCT
in guiding clinician to diagnosis or treatment of either possible relapse or GVHD or aplasia

Active

CT

Fontaine